L. Vernstrøm

Antiplatelet effect of aspirin during 24h in patients with type 2 diabetes without cardiovascular disease.

E. Grove, P. Poulsen, K. L. Funck, 2018, Thrombosis research.

Retinal vessel reactivity is not attenuated in patients with type 2 diabetes compared with matched controls and is associated with peripheral endothelial function in controls.

T. Bek, P. Poulsen, K. L. Funck, 2019, Journal of diabetes and its complications.

Low physical activity is associated with impaired endothelial function in patients with type 2 diabetes and controls after 5 years of follow-up

P. Poulsen, K. L. Funck, E. Laugesen, 2021, BMC Endocrine Disorders.

Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and perfusion in people with type 2 diabetes: a randomised trial

S. Ringgaard, C. Laustsen, K. L. Funck, 2023, Diabetologia.

Evaluation of renal oxygenation by BOLD-MRI in high-risk patients with type 2 diabetes and matched controls.

S. Ringgaard, C. Laustsen, K. L. Funck, 2022, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Differential vascular effects of aspirin in people with Type 2 diabetes without cardiovascular disease and matched controls without diabetes

E. Grove, P. Poulsen, K. L. Funck, 2019, Diabetic medicine : a journal of the British Diabetic Association.

Effects of semaglutide and empagliflozin on oxygenation, vascular autoregulation, and central thickness of the retina in people with type 2 diabetes: A prespecified secondary analysis of a randomised clinical trial.

T. Bek, P. Poulsen, K. L. Funck, 2023, Journal of diabetes and its complications.

Feasibility of Arteriograph 24 for evaluation of 24-hour pulse wave velocity and central blood pressure in patients with type 2 diabetes and non-diabetic controls

K. L. Funck, K. Hansen, L. Vernstrøm, 2024, Blood pressure monitoring.

Separate and combined effects of empagliflozin and semaglutide on vascular function: A 32‐week randomized trial

K. L. Funck, S. Gullaksen, E. Laugesen, 2024, Diabetes, obesity & metabolism.

Effects of semaglutide, empagliflozin and their combination on renal diffusion-weighted MRI and total kidney volume in patients with type 2 diabetes: a post hoc analysis from a 32 week randomised trial.

C. Laustsen, K. L. Funck, S. Gullaksen, 2024, Diabetologia.